Takeda submits NDA for Vedolizumab to treat moderate-to-severe UC in Japan
Takeda Pharmaceutical has filed a new drug application (NDA) for vedolizumab with Japan ’s Ministry of Health, Labour and Welfare to treat adult patients with moderately to severely active ulcerative colitis (UC).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Inflammatory Bowel Disease | Japan Health | New Drug Applications | Pharmaceuticals | Ulcerative Colitis